Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors-Reference-Cited by-同舟云学术

Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors

Published:2012-09 Issue:17 Volume:22 Page:5681-5684
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Miyata Junji,Kasahara Chiyoshi,Asano Toru,Ito Shinji,Seki Norio,Kato Yasuko,Morikawa Noriyuki,Nozaki Kazuyoshi,Nishimura Kouji,Akamatsu Hisashi,Taguchi Yusuke,Yamaguchi Tomonori,Abe Yoshito,Ohkubo Mitsuru,Watanabe Toshihiro,Ohta Mitsuaki,Takeuchi Makoto

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference24 articles.

1. Osteoclast differentiation and activation

2. Bone Resorption by Osteoclasts

3. Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families

4. NF-κB functions in osteoclasts

5. Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis Inhibitors;International Journal of Molecular Sciences;2023-07-10

2. Mechanistic advances in osteoporosis and anti‐osteoporosis therapies;MedComm;2023-05-11

3. Pharmacological characterization of AS2690168, a novel small molecule RANKL signal transduction inhibitor;European Journal of Pharmacology;2022-06

4. RANKL inhibition halts lesion progression and promotes bone remineralization in mice with fibrous dysplasia;Bone;2022-03

5. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis;Bone Research;2019-01-03